ClinicalTrials.gg
Active, not recruitingNCT04257136Updated Oct 23, 2023

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

A Phase 2 interventional study of VBI-S in Septic Shock, Sepsis and Hypovolemia, sponsored by Vivacelle Bio. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Vivacelle Bio · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Shock, Septic with a site in United States — 18 open to participants now, 26 under way, 1 of them phase 3. Shock, Septic · United States.

Enrollment
83rd of 116
20 · median 50
Started
2020
with 8 others
Phase 2
26 of 164
none open now
Primary completion
2023-12
later than 0 of 25 live
Registered
121st of 164
by date

Among the 164 studies in Shock, Septic with a site in United States, this one is the 83rd largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2020, is one of 26 in phase 2, reaches primary completion later than 0 of the 25 other live ones, and was the 121st registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

18 of the 164 studies in Shock, Septic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Shock, Septic with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

Read the detailed description

PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.

Randomization and blinding: This is an open label study, randomization and blinding are not applicable to this study. All patients entering this study will be treated with VBI-S.

Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.

Analysis Populations: * Safety Analysis Set (SAF): all patients who have received any amount of VBI-S. * Intent to treat (ITT) population: all patients who have received any amount of VBI-S

03

Conditions studied

  • Septic Shock
  • Sepsis
  • Hypovolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at least 18 years of age
  2. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection or an elevated procalcitonin of ≥ 2 ng/ml.
  3. Patient has a mean blood pressure \< 65 mmHg that is unresponsive to fluids currently available on the market.
  4. Sequential Organ Failure Assessment (SOFA) score >= 5.
  5. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:

    • Lactate > 2 mmol/L
    • Mottled skin
    • Decreased capillary refill of nail beds or skin
    • Fever > 38.3˚C, or 101˚F
    • Hypothermia \< 36˚C core temperature (\<96.8˚F)
    • Heart rate > 90
    • Tachypnea
    • Change in mental status
    • Significant edema or positive fluid balance (>20 mL/kg over 24 hours)
    • Hyperglycemia (>140 mg/dL) in someone without diabetes
    • White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature
    • forms)
    • Elevated C-reactive protein in serum (according to your lab's cutoffs)
    • Elevated procalcitonin in serum (≥ 2 ng/ml)
    • Arterial hypoxemia (PaO2/FiO2 \< 300)
    • Acute drop in urine output (\<0.5 ml/kg/hr for at least 2 hours despite fluid resuscitation, or about 30 ml/hour for a 70 kg person)
    • Creatinine increase > 0.5 mg/dL
    • > 1.5 or aPTT > 60 seconds
    • Absent bowel sounds (ileus)
    • High (total bilirubin > 4 mg/dL

Exclusion criteria

Exclusion Criteria:

  1. Patients with a ventricular assist device
  2. Acute coronary syndrome
  3. Pregnant
  4. Bronchospasm
  5. Mesenteric ischemia
  6. Emergency surgery
  7. Acute liver disease ( and C as examples)
  8. Liver failure with a Model for End-Stage Liver Disease (MELD) score ≥ 19
  9. Hematologic or coagulation disorders including thrombocytopenia ( count \<50,000) and associated with hemodynamically significant active bleeding.
  10. of \< 1000 mm3
  11. Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs for COVID-19 and or septic shock
  12. Patients with a known allergy to soybeans or eggs
  13. Patient is hypervolemic as assessed by CVP, ultrasound, Swan Ganz catheter, Flo-Trac, esophageal doppler, bioimpedance, ECHO, Partial carbon dioxide rebreathing (NICO), lithium dilution (LIDCO) or other method published in a peer reviewed journal
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment

    Treatment with VBI-S

    Drug: VBI-S

Interventions

  • DrugVBI-S

    VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.

06

What researchers measure

Primary outcomes

  1. The primary endpoint of this study is the proportion of patients in whom mean blood pressure increased by at least 10 mmHg with a mean blood pressure target of 60 - 65 mmHg.

    The primary endpoint of this study is the proportion of patients in whom mean blood pressure increased by at least 10 mmHg with a mean blood pressure target of 60 - 65 mmHg.

    Time frame: 10 Months

Secondary outcomes

  1. The secondary endpoint of this study is the proportion of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg

    The secondary endpoint of this study is the proportion of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg

    Time frame: 10 Months

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Dec 2023, 46 months after the start.

Of 41 phase 2 interventional studies under Shock, Septic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2020
First posted
Feb 5, 2020
StartActual
Feb 17, 2020
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04257136
Lead sponsor
Vivacelle Bio
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Feb 17, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Oct 23, 2023

Study contacts

Cuthbert Simpkins, MD, FACS
principal investigator · Vivacelle Bio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion